Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG)

BACKGROUND: Dual blockade with trastuzumab and pertuzumab combined with neoadjuvant chemotherapy (NACT) has been increasingly used for HER2-positive tumours >2 cm and/or with positive axillary lymph nodes in order to evaluate pathologic response and obtain better surgical management. SB3 is a reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Berg, Tobias, Jensen, Maj-Britt, Jakobsen, Erik H., Al-Rawi, Sami, Kenholm, Julia, Andersson, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670201/
https://www.ncbi.nlm.nih.gov/pubmed/33186804
http://dx.doi.org/10.1016/j.breast.2020.10.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670201/
https://www.ncbi.nlm.nih.gov/pubmed/33186804
http://dx.doi.org/10.1016/j.breast.2020.10.014

Ejemplares similares